After 27.7 months of follow-up in the phase III NATALEE trial, the invasive disease-free survival benefit with Kisqali (ribociclib) plus endocrine therapy was consistent across key prespecified subgroups, compared to ET alone, in patients with stage II and III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC).
Excess weight is linked to an especially high risk of developing breast cancer in postmenopausal women with cardiovascular disease, according to research from the International Agency for Research on Cancer. The study was published in Cancer.
